Vector Science & Therapeutics
Vector Science & Therapeutics supplies cGMP-manufactured, pharmaceutical-grade peptides made with pharma-grade APIs, distributed directly to physicians in orthopedic, sports medicine, and regenerative medicine practices. The company operates a US-based, FDA-licensed CDMO manufacturing partnership with independent third-party quality testing through its Verlytix division, ensuring verified chain of control from production to clinician.
- Healthcare Technology
- Medical Devices
- Biotechnology
- Hardware
Funding
Founders
Founder details are not available yet.
Product
Problem
Traditional systemic therapies for musculoskeletal conditions often require high drug doses that produce unwanted side effects and fail to concentrate treatment where it is needed most. Passive delivery methods lack the precision to target specific anatomical sites, limiting therapeutic efficacy while increasing systemic risk for patients.
Solution
Vector Science & Therapeutics develops biomechanical devices and active localized drug delivery platforms that equip clinicians with site-directed interventions for musculoskeletal care. The company's "Smart, Steered, and Sustained" approach combines data-informed formulations that respond to tissue conditions, active transdermal platforms that guide therapeutic compounds to precise anatomical targets, and sustained-release profiles that maintain therapeutic concentrations over clinically meaningful durations. Vector also operates a cGMP peptide manufacturing and distribution capability, producing investigational peptides through a US-based, FDA-licensed CDMO with independent quality testing via its Verlytix division. The company is building a distributor network to commercialize its peptide portfolio across orthopedic, sports medicine, and regenerative medicine channels.
Target Audience
Primary customers are clinicians and practices in orthopedic, sports medicine, and regenerative medicine channels, along with qualified distributors and clinical partners serving patients with musculoskeletal conditions, soft tissue injury, and degenerative joint disease including osteoarthritis.
Features
- Active transdermal platforms using iontophoresis and sonophoresis to steer therapeutic compounds to targeted anatomical regions
- Biofeedback-responsive delivery mechanisms that adapt release rates to individual patient physiology and tissue conditions
- cGMP peptide manufacturing through a US-based, FDA-licensed CDMO with independent certificate of analysis for purity, potency, and consistency on every lot
- Verlytix dedicated quality testing division providing independent analytical verification of peptide quality
- LyoGenesis Plus manufacturing and lyophilization expertise operating under cGMP, FDA, and ISO qualification standards including Class 5 cleanroom validation
- VectorMist localized atomized drug delivery platform, with a real-world evidence partnership with Caresyntax supporting The LASSO Protocol for opioid-sparing laparoscopic procedures
- Third-party distribution model directed toward qualified, credentialed distribution partners rather than direct-to-patient dispensing